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Introduction
Glioblastoma is the most common and most malignant form of primary brain tumor in adults. Understanding the contribution of the tumor microenvironment to glioma growth and response to therapy could lead to novel therapeutic approaches. Most studies concerned with tumor microenvironment have focused on the tumor vasculature.
However, glioma cells diffusely infiltrate the brain and intermingle extensively with the surrounding brain tissue. Therefore, the microenvironment of gliomas contains a complex mixture of entrapped and reactive cells. Prominent among these are glial progenitors, which are widely distributed throughout the brain and spinal cord and represent the largest populations of cycling cells in the adult central nervous system [1] [2] [3] [4] . Glial progenitors proliferate extensively in response to brain injury [5, 6] and recent studies have suggested that they also proliferate within gliomas and contribute to tumor growth [7] [8] [9] [10] [11] .
We have developed an animal model of glioblastoma that is induced by 4 [9] . This model has shown remarkable consistency, with 100% of injected animals succumbing to tumor-induced morbidity within 2 to 3 weeks. More importantly, these PDGF-driven tumors recapitulate the cardinal histologic features of human glioblastoma multiforme (GBM, WHO IV) including a high degree of proliferation (~30% Ki67 labeling index), diffuse invasiveness, glomeruloid vascular proliferation, and pseudopalisading necrosis. A compelling finding from this study was that the PDGFdriven tumors are composed of both retrovirally infected cells and uninfected glial progenitors that were "recruited" to participate in tumor formation through paracrine PDGF signaling. The recruited progenitors are highly migratory and proliferative, suggesting that they contribute to tumor growth and dispersion and are not merely entrapped cells [9, 10] . Furthermore, these features are observable clinically as we have shown that human primary glioma cells taken directly from patients as well as from a PDGF-expressing human glioma cell line are similarly capable of recruiting host-derived glial progenitors when xenografted into immunocompromised rats [12] .
In this model, the ability to distinguish between retrovirus-infected/tumorinitiating cells and uninfected/recruited progenitors on the basis of GFP expression provides a unique opportunity to compare the effects of chemotherapy on these two cell populations. In this study, topotecan, a camptothecin-class inhibitor of topoisomerase I, was directly infused into the tumor and surrounding brain through the interstitial space via convection enhanced delivery (CED) [13] . Topoisomerase I causes a single-stranded DNA break and forms a "cleavable complex" [14] thus relaxing the DNA supercoil.
Topotecan stabilizes the cleavable complex and, when a replication fork meets the complex, an irreversible double-stranded break occurs-the accumulation of which leads DNA replication and appears to be specific for cells in S-phase [15] [16] [17] [18] [19] [20] . Topotecan is a good candidate for administration via CED because it does not cross the blood-brain barrier particularly well [21] and is associated with dose-limiting toxicity when given systemically. Our own previous work with topotecan in an intracranial C6 model showed the ability to safely achieve greater than 1000-fold higher concentrations of topotecan in rat brain when delivered via CED compared to systemic delivery [22] .
We predicted that both the proliferative PDGF-producing cells as well as the proliferative recruited glial progenitors in our retroviral tumors would be susceptible to the drug's activity. We further hypothesized that, because topotecan activity is cell-cycle dependent, prolonging CED of topotecan would significantly decrease the number of residual cells from both cell populations (i.e. infected and recruited) in a time-dependent manner and thus lead to increased survival. Lastly, by analyzing tumors that recurred after treatment, we sought to determine the relative contribution of tumor cells versus recruited glial progenitors in the composition of recurrent tumors.
Materials and Methods
Retrovirus production and stereotactic injections. The PDGF-IRES-GFP retrovirus was produced as previously described [9] . Viral titers were ~10^5 CFU/mL. 5uL of viral suspension was injected into the right frontal sub-cortical white matter (stereotactic coordinates relative to bregma: 2mm right, 2mm rostral, 4mm ventral) using a 10uL syringe with a 32G needle (Hamilton, Reno, NV) at a rate of 0.2uL/min. from preliminary experiments (data not shown). At 7 days post-injection (dpi) of PDGF retrovirus, animals were anesthetized with 2% isoflurane and attached to a stereotactic head frame as above. The previous incision was re-opened and a subcutaneous pocket was formed between the animal's shoulder blades via blunt dissection. The pump body was inserted into the pocket and the cannula slowly inserted with a probe holder through the same burr hole used for virus injection. The cannula was then secured to the skull with cyanoacrylate glue. The incision was again primarily closed with nylon sutures.
Animals underwent an additional surgery also under gas anesthesia for removal of the pump and cannula apparatus.
Survival Studies. Thirty-six animals were used for 2 separate survival studies. In each experiment there were four groups of 3-5 animals each. Control animals received PBS by CED for a total duration of 7 days. Three treatment schedules for topotecan by CED were used in separate groups of animals; 1 day, 4 days, and 7 days. These animals were monitored daily for level of activity, seizure, posturing, and nasal or periorbital Short-term studies. Immediate post-treatment histologic analyses were performed on 32 tumor-bearing animals (two independent experiments, n=14-18 per experiment).
In these experiments, animals received PBS or topotecan via CED for either 1, 4 or 7 days and were immediately sacrificed (n=2-3 per treatment group, per time-point). Also, a study of the regional distribution of PDGFR-α+ glial progenitors was performed in twelve non-tumor-bearing animals (two independent experiments, n=3 untreated animals, n=3 topotecan CED x 7 days per experiment). The regional counts of PDGFR-α+ glial progenitors were also performed on tumor-bearing animals that received PBS via CED and topotecan via CED for 7 days. Mean cell counts were analyzed via one-way ANOVA with post hoc test for linear trend and/or student's t-test depending on the number of groups being compared (Prism 4.0). All counts are expressed as mean±SEM. 
Results

Chronic CED of topotecan increases survival. Median survival of control (PBS)
animals was 20 dpi. Animals given 1 day of topotecan via CED had a median survival of 23 dpi. Animals given 4 days of topotecan CED had a median survival of 31 dpi. Seven days of topotecan CED increased median survival to 54 dpi. The survival curves for all three treatment groups were statistically different from the control curve (p<0.05). The survival curve of 7-day treatment was statistically different when compared to 1-day and 4-day curves as well (p<0.05). The opposite effect was observed in topotecan-treated animals ( Figure 3C ).
Mean GFP+ cells/HPF decreased from 9.78±3.52 at day 1 to 1.33±0.65 at day 4, and to 1.00±0.73 at day 7. Means were statistically different (p=0.0103) and significant for linear trend (p=0.0071). Similarly, mean PDGFR-α+ cells/HPF decreased with prolonged treatment from 79.89±34.83 at day 1 to 10.89±4.93 at day 4, and to 0.11±0.11 at day 7. Means were statistically different (p=0.0212) and significant for linear trend (p=0.0105). Similar results were seen when we stained the topotecan-treated and PBStreated tumors for the glial progenitor marker olig2. As previously reported [9] , the tumors were predominantly composed of olig2+ cells, and 7 days of CED caused a nearly complete ablation of the olig2+ population (74.0 ± 6.03 cells/HPF for PBS treated vs 0.167 ± 0.0882 cells/HPF for topotecan-treated, p=0.0003, Figure 2S ).
To further elucidate the mechanism by which topotecan is ablating tumor cells, we measured the activated caspase-3 index in tumors treated for 7 days with CED of topotecan versus PBS. The caspase-3 index increased ~8-fold from (1.53 ± 0.491 %cells/field in PBS-treated animals to 11.8 ± 0.536 %cells/field) in topotecan-treated animals (p= 0.001) as shown in Figure 2S . These results demonstrate that topotecan is ablating tumor cells by inducing apoptosis, as previously reported [35, 36] .
Next, we tested the effects of topotecan on primary cell cultures generated from PDGF-driven tumors. We first measured topotecan effects on primary culture tumor cells with MTT assay. Incubation of tumor cells with topotecan resulted in a dose- 
dependent inhibition in tumor cell growth with greater than 80% inhibition demonstrated at 136μM topotecan (Fig 3SA) . We next examined the changes in the total number of tumor cells, GFP+/Olig2+ (tumor-initiating) and GFP-/Olig2+ (recruited) cells due to a 24 hr dose response treatment of topotecan (PBS control, 136 μM, 13 μM, 1.3 μM) . The results indicated a statistically significant drop in the number of cells in all cases (oneway ANOVA, Figure 3SB and sup table I). Similarly treating the primary cultures with topotecan (136 μM) caused a nearly complete ablation of PDGFR-α+ cells, including both the GFP+ and the GFP-subpopulations (Fig 3SC) .
To further characterize the immunophenotype of cells in the PBS-treated and topotecan-treated brain tumors, we performed immunofluorescence with a panel of antibodies against glial cell and progenitor cell markers (Olig2, NG2, Nestin, GFAP, and Sox2) and proliferation markers (Ki67 and PHH3). In the PBS treated tumors the vast majority of cells expressed PDGFRa (Fig 3) , Olig2 (Fig 2SA) , NG2 (4SA), Nestin(4SC), and Sox2 (Fig 4SE) , and approximately 30% of the cells are Ki67+ (Fig 4SG) . Double immunofluorescence analysis with olig2 and PHH3 (which selectively labels cells in G2/M phase of the cell cycle) showed that virtually all proliferating cells were olig2+ (Fig5SA). These finding are consistent with our previously published results [9, 10] . The Topotecan-treated tumors showed a nearly complete loss of cells expressing glial progenitor markers, PDGFRα (Fig3), Olig2+ (Fig 2SB), NG2 (Fig 4SB) and cells expressing proliferation markers Ki67 (Fig 4SH) and PHH3 (Fig 5SB) . There were a few NG2+ cells which were closely aligned with blood vessels and co-expressed smooth muscle actin (SMA), indicating that they are pericytes (Fig 5SD) . There were also some 
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Nestin+/Sox2+ cells scattered around the treatment site. These cells co-expressed GFAP and had the morphological features of reactive astrocytes (Fig. 6SB,D) . day post-treatment, GFP+ cells were decreased 10-fold and recruited cells were decreased 8-fold. This statistically significant trend was continued through 7 days of treatment (Fig. 3B) .
Loco-regional ablation of glial progenitors coincides
Administration of topotecan via CED produced a statistically significant survival advantage at all three tested durations. The magnitude of survival advantage steadily increased in a time-dependent manner as well, with longer treatment times associated with longer survival. It is not surprising that increased duration of topotecan administration increases cytotoxic effects because the proportion of cells cycling through S-phase (either tumor-initiating or recruited) presumably increases over time and topotecan cytotoxicity is specific for cells in S-phase [18] [19] [20] . None of the topotecantreated animals experienced morbidities related to the pump implantation or drug administration over the full 7-day course. The efficacy and safety of prolonged topotecan CED in these animals suggests that chronic CED of topotecan may be a feasible treatment modality for human glioma patients.
MRI analysis following CED of gadodiamide reveals that, even at 1 day postinfusion, the Vd is sufficient to encompass the main tumor mass (Supplementary Figure   1) . Although the Vd was not statistically greater after 7 days of infusion, gadodiamide distribution did shift anatomically to more caudal regions as well as more extensively across the corpus callosum to the contralateral side. This implies that steady-state distribution volume was achieved relatively early in treatment. Since gadodiamide distribution is at least an approximate surrogate for topotecan distribution, the MRI scans also provide indirect support that topotecan concentrations were uniformly maintained at high levels throughout the infusion period. Regional analysis of PDGFR-α+ glial 
progenitor cell distribution compared to gadodiamide distribution on MRI confirms that topotecan was present in concentrations that were toxic to glial progenitors. Nearly complete ablation of PDGFR-α+ cells was observed at the site of infusion and extended to the corpus callosum, while on the side contralateral to treatment, PDGFR-α labeling indices in white matter were statistically similar to normal brain.
While CED of topotecan efficiently killed both the tumor-initiating and recruited cell populations, all animals in the survival studies eventually succumbed to tumor recurrence. Even with 7 days of treatment, rare residual GFP+ cells could be identified through careful immediate post-treatment histological analysis. Consequently, recurrent tumors also contained GFP+ cells, indicating that tumor recurrence was derived from the progeny of retrovirus-infected cells. In recurrent tumors, however, entire regions were seen where nearly 100% of cells were GFP+. As we previously reported [9] , only ~20% not only points towards a decrease in the recruitable progenitor pool but may also indicate selection for a treatment-resistant phenotype. Perhaps these recurrent cells have cell-cycle lengths that exceed 7 days, such that they never entered S-phase during the treatment period, rendering them insensitive to topotecan. Other mechanisms of resistance to topoisomerase I-inhibition by camptothecin-class drugs have also been reported including decreased enzyme expression [28] [29] [30] [31] or decreased enzyme activity [32, 33] . Additionally, we observed that recurrent tumors had much more robust tumor vasculature than naïve tumors and that these recurrent vessels were often found to be 
